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Antimicrobial peptides (AMPs) have been proposed as a promising class of new
antimicrobials partly because they are less susceptible to bacterial resistance evolution.
This is possibly caused by their mode of action but also by their pharmacodynamic
characteristics, which differ significantly from conventional antibiotics. Although
pharmacodynamics of antibiotic resistant strains have been studied, such data are
lacking for AMP resistant strains. Here, we investigated if the pharmacodynamics of
the Gram-positive human pathogen Staphylococcous aureus evolve under antimicrobial
peptide selection. Interestingly, the Hill coefficient (kappa κ) evolves together with the
minimum inhibition concentration (MIC). Except for one genotype, strains harboring
mutations in menF and atl, all mutants had higher kappa than the non-selected
sensitive controls. Higher κ results in steeper pharmacodynamic curve and, importantly,
in a narrower mutant selection window. S. aureus selected for resistance to melittin
displayed cross resistant against pexiganan and had as steep pharmacodynamic
curves (high κ) as pexiganan-selected lines. By contrast, the pexiganan-sensitive
tenecin-selected lines displayed lower κ. Taken together, our data demonstrate that
pharmacodynamic parameters are not fixed traits of particular drug/strain interactions
but actually evolve under drug treatment. The contribution of factors such as κ and
the maximum and minimum growth rates on the dynamics and probability of resistance
evolution are open questions that require urgent attention.
Keywords: resistance evolution, Hill coefficent, pharmacodynamics, pexiganan, melittin
INTRODUCTION
Bacterial drug resistance is a growing problem (Davies and Davies, 2010). Under conventional
antibiotic treatment resistance evolves frequently (Levy and Marshall, 2004; Davies and Davies,
2010). Solving this problem requires new approaches including prudent use, understanding
evolutionary dynamics (zur Wiesch et al., 2014) and the identification of new drug candidates
(WHO, 2012) that are likely to avoid evolution of resistance (Czaplewski et al., 2016).
Antimicrobial peptides (AMPs) have been proposed as promising new drug candidates
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(Zasloff, 2002; Fjell et al., 2012; Mylonakis et al., 2016; Pfalzgraff
et al., 2018). Though resistance against AMPs evolves readily in
in vitro systems (Perron et al., 2006; Habets et al., 2012; Dobson
et al., 2013; Makarova et al., 2018), this does not seem to be the
case in vivo. Based on pharmacodynamic studies of AMPs, one of
their alleged advantage is that evolution of resistance has a much
lower probability compared to antibiotics (Yu et al., 2018).
Pharmacodynamics are based on time-kill curves. Regoes
et al. (2004) analyzed time-kill curves using a pharmacodynamic
model that is closely related to Emax models (Mueller et al.,
2004). Pharmacodynamic functions link drug dosage and
bacterial growth or death rates. Four parameters are important
for this model (Regoes et al., 2004): the Hill coefficient
(κ), i.e., the slope, the maximal bacterial growth rate in the
absence of antimicrobial (9max), the minimal bacterial growth
rate at high concentrations of antimicrobial (9min), and the
pharmacodynamic minimum inhibition concentration (zMIC)
(Regoes et al., 2004).
The steepness of pharmacodynamic curves, as described by
κ, is much greater for AMPs than for antibiotics (Yu et al.,
2016). The maximum killing effect of AMPs is much stronger
than that of antibiotics, as measured via the speed of killing
(Fantner et al., 2010; Yu et al., 2018). Consequently, AMPs
display a narrower mutation selection window compared to
antibiotics, thus resistance toward AMPs is less likely to evolve
(Yu et al., 2018). Moreover, AMPs cocktail have higher kappa
values than single AMPs (Yu et al., 2016); a crucial information
for combinational therapy, a proposed antibiotic replacement
regimes (Walkenhorst, 2016).
Despite short comings, the minimum inhibition
concentration (MIC) is still the most common bioassay to
explore cross resistance (Brauner et al., 2016; Wen et al., 2016).
The importance of pharmacodynamic parameters in predicting
drug resistance evolution has been reported in several studies
(Chevereau et al., 2015; Lukacˇišinová and Bollenbach, 2017). In
addition to in vivo infection dynamics studies (Dobson et al.,
2014; McGonigle et al., 2016; Zanchi et al., 2017; El Shazely et al.,
2019), pharmacodynamic approaches are useful to understand
how antibiotics and antimicrobial peptides eradicate bacteria
in physiological systems (Yu et al., 2016). It is assumed that the
shape of pharmacodynamic curve does not change (Craig, 1998).
Here, we use a pharmacodynamic approach, that has been
previously described to generate a sigmoid dose–response
relationship (Bonapace et al., 2002; Regoes et al., 2004; Sampah
et al., 2011; Yu et al., 2016), to study the evolution of
AMP resistance. We explored whether the steepness of the
pharmacodynamic curve (described by the Hill coefficient, κ),
can evolve. It is the first time that pharmacodynamic parameters
(kappa, 9min, 9max) of AMP resistant strains have been
investigated. In this study, a standardized in vitro time-kill
curve assay for the human pathogen, Staphylococcous aureus,
which has been selected against either pexiganan, melittin (this
study), tenecin 1 or tenecin 1 + 2 (strains from our previous
study (Makarova et al., 2018)) was performed. We address two
questions. (i) Do kappa, 9min, 9max evolve? (ii) Does cross
resistance or cross sensitivity influence the pharmacodynamic
parameters: kappa,9min,9max and zMIC?
MATERIALS AND METHODS
Bacterial Strains and Culturing
Conditions
Staphylococcus aureus SH1000 was used in this study. Non-cation
adjusted Mueller Hinton Broth (MHB) (PanReac AppliChem,
Cat #413788-1210) was used for bacterial cultures. Bacterial
cultures were incubated at 37◦C with shaking at 180 rpm and
plated on Mueller Hinton Agar (MHA). The later was prepared
by adding 15 g/l bacteriological Agar Agar (Carl Roth, Cat
#2266.2) to MHB.
Antimicrobial Peptides
We used two different AMPs: pexiganan and melittin. Pexiganan
is a synthetic AMP, an analog of Magainin II that was originally
isolated from the epidermis of the African clawed frog, Xenopus
laevis (Zasloff, 1987) (Pexiganan was a kind gift from Michael
Zasloff). Melittin (purity > 95%, GenScript, Cat #RP10290) is
a synthetic AMP known to be an analog of the main toxin of
bee venom (Habermann, 1972). To avoid multiple freeze-thaw
cycles, peptides were re-suspended in (1:1 v/v) sterile distilled
water and glycerol (Sigma life science, Cat #G5516) to the final
concentration of 5 mg/ml and stored at−20◦C in sterile vials.
Selection Experiment
The selection experiment was done according to Makarova
et al. (2018). Briefly, preadapted S. aureus SH1000 glycerol
stocks were stored at −80◦C from the above-mentioned study.
Five preadapted strains were inoculated into 10 ml MHB and
incubated overnight with shaking at 37◦C. The cultures were then
diluted 1:1000 and incubated at 37◦C in 50 ml polypropylene
Falcon tubes (Th.Geyer, Cat #7696724) containing 3.7 ml MHB.
Short pre-adaptation was carried out by serial passage every
24 h for 4 days, with daily measurements of optical density
at 600 nm, contamination checks by plating out on MHA
and cryopreservation of culture aliquots at −80◦C in 12%
glycerol solution.
For the selection protocol, the experiment was performed
at 37◦C in a microplate reader (Synergy 2, Biotek). To avoid
attachment of the peptides to the plastic surfaces, flat bottom
polypropylene non-binding 96-well plates were used (Greiner
Bio-One, Cat #655261). To minimize evaporation, the 96-well
plates were covered with clear polystyrene lids with condensation
rings (Greiner Bio-One, Cat #656171). The plates were filled with
200 µl of MHB per well. Growth dynamics were monitored by
optical density measurement at a wavelength of 600 nm every
10 min. Measurements were preceded by a moderate shaking for
10 s and continued for 24 h. For each of the five replicate lines
there were two experimental conditions: pexiganan or melittin, as
well as two controls: negative control, and non-selected control.
The serial passage started at 1 µg/ml for pexiganan (MIC of
the preadapted strains toward pexiganan was 2–4 µg/ml) and
2 µg/ml melittin (MIC of the preadapted strains toward melittin
was 4–8 µg/ml). Overnight cultures of the five replicate lines
were diluted 1:100 and sub-cultured until OD600 of 0.5. Ten µl
of these cultures were inoculated into each treatment and control
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wells resulting in final total volume of 200 µl. Four µl (2%) of
the culture were transferred every 24 h to a fresh 96 well plate.
The concentration of AMPs was doubled each week. Plates were
regularly checked for contamination. Glycerol was added to the
rest of the cultures to the final concentration of 12% and the
plates were stored at −80◦C. During the selection experiment, a
strain required 5–7 days to evolve resistance such that the culture
could survive a two-fold increase in the AMP concentration.
The selection experiment continued for 8 weeks where MIC was
duplicated 64 folds for both pexiganan and melittin (64× MIC).
Antimicrobial Susceptibility Testing
Minimal inhibitory concentration (MIC) was determined using
a broth micro-dilution method. Briefly, 5 µl (1 × 105 CFU/ml)
of 1:100 dilution of the mid-exponential phase bacterial
culture (OD600 = 0.5) were inoculated into the wells of
polypropylene V-bottom 96-well plates (Greiner Bio-One,Cat
#651261) containing two-fold dilution series of the stressor in a
total volume of 100 µl MHB per well. The assay was performed
in triplicate. The plates were incubated at 37◦C in a humidity
chamber. The lowest concentration that inhibited visible bacterial
growth after 24 h of incubation is the MIC. Visual observations
were confirmed by heat maps generated by Gen 5 software
(Biotik) of OD600 measurements on a microtiter plate reader
(Synergy 2, Biotek).
Growth Curves
Growth curve assays were performed using a microtiter plate
reader (Synergy 2, Biotek). The changes in turbidity at OD600
of the selected mutant lines and the non-selected controls were
monitored in un-supplemented MHB. For this, 20 µl of 1:10
dilution of mid exponential phase of bacterial culture were
inoculated into 180 µl MHB. Each assay had three replicates.
The measurements were taken at 10 min intervals during 38 h of
incubation at 37◦C, with 5 s shaking before each reading. Growth
parameters such as final OD, the maximum growth rate (Vmax)
and lag time were calculated with Gen5 software (Biotek).
DNA Isolation
Genomic DNA for whole genome sequencing was isolated using
Quick-DNA Fungal/Bacterial Microprep kit (Zymo Research, Cat
#D6007) following manufacturer’s instructions. Briefly, 2 × 108
log phase bacteria were resuspended in 200 µL of phosphate
buffer saline (PBS) (pH = 7.4, Chem solute, Cat #8035.0100)
solution. Then, 750 µL of bashing beads buffer were added
and the mixture was transferred into bashing beads lysis tubes.
The tubes were placed in a homogenizer (Retsch MM 400)
at maximum speed for 5 min. The mixture was centrifuged
shortly at 10,000 g for 1 min. Then, 400 µL of supernatant
were transferred to a spin filter. The filtrate was chemically
lysed by adding 1200 µL genomic lysis buffer. Then the
mixture was passed into a zymo-spin IC column, centrifuged
and washed twice, first, with DNA Pre-wash buffer, then, with
DNA wash buffer. Finally, the DNA was eluted using 20 µL
of DNA elution buffer. The DNA quantity and quality were
estimated by measuring the optical density at A260/280 using the
Nanodrop spectrophotometer (Thermo Scientific) and agarose
gel electrophoresis.
Sequencing
To identify mutations in experimentally evolved populations
and strains, the haploid variant calling pipeline snippy v3.2
(Seemann, 2015) was used with default parameters [minimum
read mapping quality (–mapqual) 60, minimum base quality (–
basequal) 20, minimum coverage (–mincov) 10, and minimum
proportion of variant coverage (minfrac) 0.9] as previously
described in Makarova et al. (2018). Briefly, quality-filtered
adaptor-trimmed reads were aligned to the SH1000 reference
genome using bwa (Li, 2013). The Bayesian genetic variant
detector freebayes (Garrison and Marth, 2012) was used to detect
single-nucleotide polymorphisms, insertions, deletions, multi-
nucleotide polymorphisms, as well as composite insertion and
substitution events.
Killing Curves
For pexiganan- and melittin-selected strains, pexiganan was
serially diluted (two-fold concentration gradient), starting with
256×MIC (1024µg), in 96-well plate. Approximately, 2–3× 106
log-phase bacteria were added to a total volume of 100 µl. The
plates were incubated at 37◦C. Killing by AMPs is rapid (Sochacki
et al., 2011; Rangarajan et al., 2013), therefore dose response was
monitored within 60 min (Yu et al., 2016). Ten microliters of
bacterial suspension were taken out after 30 s and then every
20 min, then immediately diluted in PBS and plated on square
solid MHA plates. These solid agar plates were transferred into
30◦C incubator. CFU were counted 24 h later. The incubation of
plates at 30◦C facilitate counting CFU before colonies overgrow
and overlap. The limit of detection in our system is 14 CFUs.
Following the same protocol, we determined the killing curves
for the tenecin 1 and tenecin 1 + 2-selected strains available
in the laboratory from a former study (Makarova et al., 2018).
For these 36 genotypically unique strains, pexiganan was serially
diluted starting with 16 × MIC (64 µg), to save material as
it was known from MIC results that they do not share cross
resistance to pexiganan.
Data Analysis
Statistical analysis was done in R (R Core Team, 2013).
MIC Analysis
The best fit was obtained when the MIC values were log2
transformed. A linear model was fitted to the transformed
data. Treatment and mutation were considered as explanatory
variables in the model. Several normality checking functions were
used to test normality assumptions such as “bptest” (Breusch-
Pagan test against heteroskedasticity) and “dwtest” (Durbin-
Watson test for autocorrelation of disturbances) from “lmtest”
package (Hothorn et al., 2019), “gvlma” (Global Validation of
Linear Models Assumptions) from “gvlma” package (Pena and
Slate, 2012) and “durbinWatsonTest” from “car” package (Fox
et al., 2012). The function “anova” was used to analyze the model
and extract F-statistics and degrees of freedom. The “mean”, “sd”
and “var” functions were used to calculate the mean, standard
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deviation, standard error and variance. For analysis of contrasts,
post hoc comparisons were performed using “lsmeans” function
with a “tukey” adjustment (Lenth and Lenth, 2018). We used
the function “visreg” from package “visreg” (Breheny et al.,
2019) to visualize the contrast plot of the treatment effect as
extracted from the model.
Growth Curve Analysis
Growth parameters (Vmax, duration of lag phase and final OD
600) were analyzed by using the “lm” function for linear models.
For contrasts, post hoc tests were performed using “lsmeans” and
“visreg” functions as described before.
Modeling Killing Curves
A Hill function was used to model the killing curve as previously
described (Regoes et al., 2004; Yu et al., 2016). Briefly, generalized
linear regression was used to determine growth and killing
rates of bacteria from the time-kill curves as the change of
CFUs over time. The CFU data were log-transformed (log10).
Using the rjags package (Plummer et al., 2016), the growth
and killing rates were fitted and extracted based on Markov
Chain Monte Carlo (MCMC) method and the pharmacodynamic
curves were generated.
Analysis of Pharmacodynamic Parameters
The pharmacodynamic parameters were extracted from the
MCMC output. We tested whether the pharmacodynamic MIC
of various S. aureus strains selected against AMPs segregated
by selection treatment and/or by mutation. The zMIC was log2
transformed and a linear model was fitted as described above.
A generalized linear model with gamma distribution was fitted
to analyze 9max variances across S. aureus strains with different
selection treatment and different mutation. The 9min variances
were analyzed using a linear model. The Hill coefficient κ data set
was normalized by log-transformation (log10) then a linear model
was fitted. Post hoc analysis was performed as described above.
RESULTS
Resistance Evolved at a Cost
After 8 weeks of selection, all lines were able to grow in the
presence of 256 µg/ml pexiganan or 512 µg/ml melittin, which is
equivalent to 64-fold of MIC of non-selected preadapted strains
for both stressors. According to minimum inhibition sensitivity
test, MIC pexiganan segregated by treatment (F(2,40) = 143.2300,
p < 0.0001, Figure 1A), but not by mutation (F(2,40) = 1.8769,
p = 0.166, Figure 1B). S. aureus evolved pexiganan resistance
both when selected against pexiganan (T = 16.554, df = 42,
p< 0.0001, Figure 1) and melittin (T = 9.121, df = 42, p< 0.0001,
Figure 1). Moreover, MIC pexiganan differed significantly between
pexiganan- and melittin-selected lines (T = 7.432, df = 42,
p < 0.0001, Figure 1A). Pexiganan-selected lines showed cross
resistance to melittin (T = 8.457, df = 42, p < 0.0001,
Supplementary Table S1).
Antimicrobial peptides-selected strains had consistently
slower growth rates in the exponential phase for both,
pexiganan (Vmax: T = 2.821, df = 42, p = 0.01, Figure 2A)
and melittin-selected strains (Vmax: T = 3.146, df = 42, p = 0.008,
Figure 2A) compared to non-selected controls (Supplementary
Figure S1). However, lag phases (lag Pexiganan: T = 0.356, df = 42,
p = 0.932, lag Melittin: T = 1.234, df = 42, p = 0.440, Figure 2B)
and final population sizes measured as OD did not differ (Final
ODPexiganan: T = –1.313, df = 42, p = 0.396, Final ODMelittin:
T = 0.592, df = 42, p = 0.825, Figure 2C).
Genome Sequencing Reveals Mutations
in a Number of Loci Related to Selection
Treatment
Whole genome sequencing of the selected mutants and the
non-selected controls (at the single colony level) showed
differences between treatments. In each melittin-resistant strain
at least four mutations in pmtR (also known as ytrA), vraG
(also known as bceB), atl, and namA genes were identified.
All those mutations are known to be involved in cell wall
stress tolerance and detoxification (see also Supplementary
Table S2 for a full list of mutations). The mutations included
stop gain for pmtR, missense (c.1727C > T p.Ala576Val for
8 strains and c.924T > A p.Ser308Arg for nine strains) for
vraG, frameshift for atl (c.2705_2706dupAT p.Ala903fs) and
synonymous (c.477G > A p.Ala159Ala) for namA. Interestingly,
we found the same pmtR stop-gain mutation (c.77T > A
p.Leu26∗) in all melittin-selected strains in this study, which
has previously been described for melittin-selected S. aureus
lines (Johnston et al., 2016) and for tenecin-selected S. aureus
(Makarova et al., 2018). For all pexiganan-selected strains, a
missense mutation (c.571C > G p.Arg191Gly) for menF gene
and stop gains and disruptive in-frame deletion mutations
(c.2331_2342delTACTGTTACTAA p.Tyr777_Lys781delinsTer)
for atl gene were consistent. Two strains only harbored these two
mutations, while the other pexiganan-selected strains carried
additional mutations either conservative in-frame insertion
(c.178_192dupTCACAAGGTTCTATT p.Ser60_Ile64dup) in
vraF gene (also known as bceA), or missense (c.884C > T
p.Ser295Phe) in rpoA gene or both. Six pexiganan mutants had
a missense in rpoA, one had conservative in-frame insertion in
bceA gene while six strains had mutations in both loci.
Killing (Dose-Response) and
Pharmacodynamic Curves
We tested in vitro killing of pexiganan using different AMP
resistant S. aureus strains (pexiganan, melittin, tenecin 1
and tenecin 1 + 2-selected strains) and their respective
controls. Time-kill curves were obtained by counting viable
CFUs after treatment with various concentrations of pexiganan
(Supplementary Figure S2). The CFUs of surviving bacteria
strongly decreased as a function of time at higher pexiganan
concentrations, however slight increases were noticed at lower
concentrations. There are four measurements of the bacterial
density during the first 60 min after exposure to pexiganan.
This time interval was appropriate to statistically estimate the
bacterial net growth rate at a given concentration and construct
the pharmacodynamic curves (Supplementary Figure S3).
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FIGURE 1 | Log2 MIC of pexiganan and melittin resistant S. aureus strains compared to procedural controls tested against pexiganan separated by treatment (A) or
by mutation (B) (C and none: unselected control, M: melittin-selected strains with mutation in namA, vraG, atl, and pmtR gene loci, P: pexiganan-selected strains
segregated into four genotype variants with mutation in menF, atl, and vraF, rpoA or both, blue line: mean, gray box: 95% confidence intervals). According to
minimum inhibition sensitivity test, MIC pexiganan segregated by treatment (F(2,40) = 143.2300, p < 0.0001, Figure 1A) but not by mutation (F(2,40) = 1.8769,
p = 0.166, Figure 1B).
FIGURE 2 | Growth parameters of evolved AMP-resistant Staphylococcus aureus in relation to treatment [Vmax (A), lag phase (B), final OD (C)]. (Con: unselected
control, M: melittin-selected strains, P: pexiganan-selected strains, blue line: mean, gray box: 95% confidence intervals).
TABLE 1 | Parameter estimates and their standard errors.
S. aureus MIC (µg/ml) zMIC (µg/ml) 9min (h−1) 9max (h−1) κ
Con1 72.53 ± 5.81 66.76 ± 7.42 −9.90 ± 0.22 0.23 ± 0.06 2.86 ± 0.13
P 768.00 ± 86.54 300.32 ± 23.33 −7.60 ± 0.30 0.26 ± 0.06 15.32 ± 1.32
M 247.46 ± 8.53 283.19 ± 30.16 −8.20 ± 0.21 0.11 ± 0.03 15.10 ± 1.42
Con2 48.00 ± 7.16 22.94 ± 3.77 −9.04 ± 0.16 0.46 ± 0.07 4.84 ± 0.53
T1 49.78 ± 3.86 21.02 ± 2.06 −8.86 ± 0.13 0.41 ± 0.03 4.02 ± 0.34
T1T2 53.33 ± 4.54 19.29 ± 2.86 −7.97 ± 0.35 0.27 ± 0.03 4.18 ± 0.69
MIC, minimum inhibition concentration determined by a two-fold dilution protocol; zMIC, pharmacodynamic MIC; 9min, the minimum bacterial net growth rate at high
pexiganan concentrations; 9max, the maximum bacterial net growth rate; κ, the Hill coefficient; Con, passaged non-selected control for pexiganan- and melittin-selected
lines (Con1) and for tenecin-selected lines (Con2); P, pexiganan-selected S. aureus; M, melittin-selected S. aureus;T1, tenecin 1-selected S. aureus; T1T2, tenecin1 + 2-
selected S. aureus. Pexiganan (P) and Melittin (M) selected S. aureus lines evolved higher kappa values (Bold) compared to their unselected controls (Con1).
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The average values of pharmacodynamic MICs (zMIC) and
those determined by a two-fold dilution protocol (MIC) are
listed in Table 1. The estimated pharmacodynamic zMICs differs
slightly from the MIC measurements.
The pharmacodynamic MIC (zMIC) segregated by treatment
(F(5,283) = 127.67, p < 0.0001, Figure 3A). The pexiganan
resistant strains had a zMIC higher than its respective control
(T = 9.451, df = 238, p < 0.0001, Figure 3A). Melittin resistant
strains had a cross resistance to pexiganan (T = 7.911, df = 238,
p < 0.0001, Figure 3A). The zMIC values of pexiganan- and
melittin-selected S. aureus did not differ significantly (T = 0.542,
df = 238, p = 0.9944, Figure 3A). Tenecin 1 and tenecin
1 + 2 strains were as sensitive to pexiganan as their respective
non-selected controls (tenecin1-control: T = –0.782, df = 238,
p = 0.9703; tenecin1+ 2 -control: T = –1.522, df = 238, p = 0.6503,
Figure 3A). zMIC did not segregate by mutation within each
treatment, for example vraF (bceA) mutants are not significantly
different from menF-atl mutants (T = 1.569, df = 232, p = 0.9184,
Figure 3B).
9max and 9min
9max values were found to be almost identical across treatments
(Figure 4). This suggests that growth rates of bacteria in low
concentration of AMP(s) were presumably close to the natural
growth rate (Yu et al., 2016). It is interesting that differences in
Vmax, referred to earlier, were not reflected by differences in
9max values.
9min values segregated by treatment (F(5,232) = 10.285,
p < 0.0001, Figure 5A). Pexiganan- and melittin-selected
S. aureus had higher 9min values than the non-selected controls
(P-Con: T = 6.130, df = 238, p < 0.0001; M-Con: T = 4.049,
df = 238, p = 0.001, Figure 5). The 9min values for tenecin
1- and tenecin 1 + 2-selected strains were not different from
non-selected controls (T1-C: T = 0.511, df = 238, p = 0.995;
T1T2-C: T = 2.759, df = 238, p = 0.0678, Figure 5A). However,
tenecin 1-selected S. aureus had a slightly lower9min values than
tenecin1 + 2-selected strains (T = –3.037, df = 238, p = 0.0315,
Figure 5A). Pexiganan resistant strains had almost equal 9min.
Tenecin-selected S. aureus with mutation in the nsa operon had
uniquely higher 9min than the non-selected control (T = 5.303,
df = 232, p < 0.0001, Figure 5B), having an additional mutation
in the rpo operon at C or B loci would decrease the 9min values
significantly (T = –5.494, df = 232, p< 0.0001, Figure 5B).
Does Kappa Evolve?
Pexiganan-selected S. aureus had significantly higher kappa
values than non-selected controls (T = 11.191, df = 238,
p < 0.0001, Table 1 and Figure 6A), resulting in very
steep pharmacodynamic curves (Supplementary Figure S3).
Pexiganan-selected strains lacking mutations in both vra (bce)
and rpo operons showed however a kappa value as low as the
non-selected controls (T = 0.570, df = 232, p = 1.00, Figure 6B);
therefore, a shallower pharmacodynamic curve compared to
pexiganan resistant mutants (Supplementary Figure S3). The
cross resistance of melittin-selected strains toward pexiganan
seemed to result in kappa values greater than in the control strains
(T = 10.353, df = 238, p < 0.0001, Table 1 and Figure 6A).
Tenecin-selected strains were as sensitive as their non-selected
control and for that kappa was consistent (T1-Con: T = –1.521,
df = 238, p = 0.651; T1T2-Con: T = –2.147, df = 238, p = 0.267,
Table 1 and Figure 6A). However, tenecin-selected strains with
mutations in the pmt operon had a kappa value lower than non-
selected controls (T = –3.617, df = 232, p = 0.0185, Figure 6B).
DISCUSSION
Our study was probably the first to explore the co-evolution
of pharmacodynamic parameters (κ, 9min, 9max) and bacterial
AMP resistance. We found that AMP resistance evolution in
S. aureus resulted not only in increasing MICs, but, importantly
in some strains also in changes in the Hill coefficient (κ),
resulting in steeper pharmacodynamic curves. Kappa evolved in
a mutation dependent manner. Despite the slower AMP selected
bacterial growth rate, as captured by Vmax extracted from growth
curve analysis, the maximum bacterial growth rate in absence of
pexiganan, 9max, did not evolve. The maximum killing rate at
high concentration of pexiganan, 9min, co-evolved with in vitro
AMP selection. Cross resistance (melittin-selected strains) and
cross sensitivity (tenecin 1- and tenecin 1 + 2-selected strains)
affected both zMIC and kappa but not9min and9max.
Our selection protocol covered several weeks. This is
consistent with treatment regimens for complicated S. aureus
infections, where 4–6 weeks of intravenous therapy has been the
standard practice for over half a century and continues to be
recommended (Tong et al., 2015). Although in vitro selection
of S. aureus (SH1000) against tenecin 1 and a combination
of tenecin 1 + 2 lasted for 8 days (Makarova et al., 2018),
following the same protocol herein, to evolve pexiganan and
melittin resistance required 8 weeks. Moreover, in one of our
former studies S. aureus (JLA513) extinction was observed after
2 weeks of pexiganan selection (Dobson et al., 2013), which
was not repeated in the current study. The explanation of
differences in pathogen/drug evolutionary dynamics remains
poorly understood (Chevereau et al., 2015).
The fitness cost of a pathogen can be inferred from a reduced
growth rate in vivo (Majcherczyk et al., 2008) or in vitro
(zur Wiesch et al., 2010). Here, we find clear evidence for
costly resistance as measured in slower growth rate (Vmax).
However, unlike tenecin-selected lines (Makarova et al., 2018),
lag phase for both pexiganan and melittin AMP-selected lines
was not prolonged.
Selecting S. aureus against melittin resulted in consistent
patterns of mutations. All melittin-resistant strains had the
following four mutations: stop gains for pmtR, missense for bceB,
frameshift for atl and synonymous for namA gene. Mutation
in pmtR was identical to the stop-gain mutation described in
melittin-selected S. aureus JLA513 (Dobson et al., 2013) and
in tenecin-selected S. aureus SH1000 (Makarova et al., 2018).
Bacteria harboring a mutation in the gene encoding GntR-
type transcriptional repressor, PmtR (Joo et al., 2016b), can
continuously efflux AMPs (Cheung and Otto, 2018; Cheung
et al., 2018) along with Phenol-soluble modulins (PSMs), a
bacterial secreted cytotoxin (Joo et al., 2016a). Mutation in
namA, a gene encoding flavin oxidoreductases, was previously
reported for antibiotic stress response (Loi et al., 2019). All
Frontiers in Microbiology | www.frontiersin.org 6 February 2020 | Volume 11 | Article 103
fmicb-11-00103 February 13, 2020 Time: 18:19 # 7
El Shazely et al. Pharmacodynamics of AMPs in S. aureus Evolve
FIGURE 3 | Estimated pharmacodynamic MIC (zMIC) of AMP-selected versus AMP-sensitive S. aureus segregated by treatment (A) or by mutation (B). (Con:
passaged non-selected control for pexiganan- and melittin-selected lines (Con1, none1, gray) and for tenecin-selected lines (Con2, none2, gray), P:
pexiganan-selected S. aureus (red) segregated into 4 genotype variants with mutation in menF, atl, and vraF, rpoA or both, M: melittin-selected S. aureus (blue) with
mutation in namA, vraG, atl, and pmtR gene loci,T1: tenecin 1-selected S. aureus (yellow) and T1T2: tenecin1 + 2-selected S. aureus (yellow) harboring a mutation in
either pmtR/S or nsaS/R gene loci which might be accompanied by a mutation in rpoC/B). The boxplots show the first to the third quartiles and the median. The
bars indicate the 1.5 interquartile of the lower and upper quartiles. The dots represent outliers.
FIGURE 4 | Variation of 9max values of AMP-selected versus AMP-sensitive S. aureus predicted by MCMC segregated by treatment (A) or by mutation (B). 9min
refers to the maximal growth rate of bacteria at low pexiganan concentration. The Boxplot description, abbreviations and color reference are previously described in
Figure 3.
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FIGURE 5 | Variation of 9min of AMP-selected versus AMP-sensitive S. aureus predicted by MCMC segregated by treatment (A) or by mutation (B). 9min describes
minimal growth rate of bacteria under at high pexiganan concentration. 9min values segregated by treatment (F(5,232) = 10.285, p < 0.0001). The Boxplot
description, abbreviations and color reference are described in Figure 3.
FIGURE 6 | Variations of Hill coefficients κ of AMP-selected versus AMP-sensitive S. aureus predicted by MCMC segregated by treatment (A) or by mutation (B).
Kappa predicts the shape slope of the pharmacodynamic curve, the larger the κ value, the steeper is the pharmacodynamic curve. The Boxplot description,
abbreviations and color reference are described in Figure 3.
pexiganan-selected lines had mutations in atl and menF genes.
Autolysis decreased in an atl (Bi functional autolysin gene)
S. aureus mutant (Schlag et al., 2010). Some pexiganan-selected
lines had a mutation in vraF (bceA) gene, rpoA gene or both. The
vraFG gene (also designated as bceAB gene) codes for bacitracin
export permease protein VraFG (BceAB), an ABC transporter
controlling BceSR, a bacterial two-component systems (TCSs)
associated with antimicrobial susceptibility (Yoshida et al., 2011).
VraFG transporter sense the presence of cationic AMPs and
transmit signaling through BceS (also known as NsaS and
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GraS) to activate BceR (also known as NsaR and GraR)-
dependent transcription (Falord et al., 2012). Increased levels
of phosphorylation due to point mutations in the bceSR (also
known as nsaSR) operon leads to constitutive expression of
BceAB/VraGF which facilitates detoxification by efflux (Coates-
Brown et al., 2018). A mechanism by which S. aureus can evolve
resistance to nisin (Arii et al., 2019), bacitracin (Hiron et al.,
2011), and likely to other AMPs (Johnston et al., 2016; Makarova
et al., 2018) such as human host defense peptides. Such resistance
is a prerequisite for establishing chronic infection (Chaili et al.,
2015). Many of the mutations identified herein were described
previously in S. aureus clinical isolates from patients (Hafer
et al., 2012). In summary, such mutations facilitate acquisition
of drug resistance, contribute to immune evasion or alter host
immune function (DeLeo et al., 2009). It is noteworthy that a
recent large-scale whole-genome comparison in Pseudomonas
aeruginosa showed that experimental antimicrobial resistance
evolution reflects and predicts changes in naturally evolved
clinical isolates (Wardell et al., 2019).
By analyzing the data with a four-parameter
pharmacodynamic model (Regoes et al., 2004), we found
that the Hill coefficient, kappa, evolves. Despite its potential
importance (Yu et al., 2018; Firsov et al., 2003), kappa is often
missed in many pharmacodynamic models, where it is set to
1 or another fixed value for all drugs and referred to as the
sigmoidal constant (Craig, 1998; Thomas et al., 1998; Lenhard
et al., 2015), even though kappa differs distinctly for different
drugs (Yu et al., 2016). Using a different modeling approach,
Chevereau et al. (2015) tested a dose-response curves of 78
genome-wide Escherichia coli gene deletion strains for a number
of antibiotics. They found that the steepness of the dose-response
curve varied with drug, but dose-sensitivity (the Hill coefficient
k or n as denoted in Chevereau et al. (2015) of the mutants
was the same as that of the wild types. Their strain collection
did not contain strains which were specifically selected for
resistance against the tested drugs. Moreover, in contrast to our
approach, they modeled the pharmacodynamics for positive
growth only and continuously adjusted the drug concentration.
Pharmacodynamic parameters, including the Hill coefficient,
play an important role in determining the population size of
persistent S. aureus (Johnson and Levin, 2013) and P. aeruginosa
(Hengzhuang et al., 2012) and therefore the probability of
infection. In previous work it has been shown that the Hill
coefficient relates to the probability of resistance evolution
against AMPs (Yu et al., 2018). Whether or not a change in the
Hill coefficient, driven by bacterial mutations, contributes to
the speed and probability of resistance evolution will require
additional work.
Kappa of pexiganan resistant strains, with mutations in
vraF (bceA) and/or rpoA genes, were markedly high resulting
in a very steep pharmacodynamic curve. Additionally, killing
curves of melittin-selected strains, which showed cross resistance
toward pexiganan, were as steep as pexiganan resistant
strains. Interestingly, pexiganan-selected S. aureus which harbor
mutations in menF and atl genes only, uniquely recorded
extremely low kappa values. Linking variations in kappa values
among AMP resistant strains and whether resistance mutations
per se are costly or mitigated by compensatory mutations needs
farther investigation. The steepness of the pharmacodynamic
curve (kappa) determines the width of the mutation selection
window MSW (Yu et al., 2018). Firsov et al. (2003, 2006) showed
that the size of the (MSW) in S. aureus clinical isolates correlates
positively with selection for resistance in fluoroquinolones,
vancomycin, and daptomycin. We can conclude that MSW as
inferred by kappa relies on both tested drug type and bacterial
genetic background.
The current study is a proof of principle that shows
that pharmacodynamics do evolve beyond MIC with AMP
resistance. Applying this finding to all kind of host pathogen
interactions and investigating co-evolution to host defense
antimicrobial peptides or other antimicrobials will be useful
to understand the dynamics of drug resistance evolution. For
example, S. aureus on the skin are continuously under selection
pressure from human AMPs. Along with in vivo infection
dynamics studies (El Shazely et al., 2019), our study might shed
some light on understanding host pathogen relationship during
persistent infection. Understanding how antimicrobial peptides
eradicate bacteria in physiological system, necessitates studying
pharmacodynamics of AMPs in vitro (Yu et al., 2016) and in vivo
(Zanchi et al., 2017).
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FIGURE S1 | Fitness costs inferred by growth parameters over mutation/operon
in relation to the selective pressure treatment. [Vmax (A), lag phase (B),
final OD (C)].
FIGURE S2 | Time-kill curves of AMP selected S. aureus (SH1000) versus
non-selected controls exposed to various concentrations of pexiganan. See
Supplementary Table S1 for a full list of tested strains.
FIGURE S3 | The pharmacodynamic curves of AMP resistant versus AMP
sensitive S. aureus segregated by treatment (A) or by mutation (B). The curves
illustrate the effects (reflected as net bacteria growth rate) of increasing the
concentration of pexiganan. The ribbon represents 95% of confidence interval.
TABLE S1 | List of the MIC values of pexiganan and melittin resistant strains and
their procedural controls tested against pexiganan and melittin. The MIC values of
tenecin 1- and tenecin 1 + 2-evolved strains as well as their unselected controls
tested against pexiganan only are listed below. The results were determined by a
two-fold dilution protocol.
TABLE S2 | Mutation/operon list of pexiganan and melittin resistant S. aureus
strains and their procedural controls. (M: melittin-evolved strains, P: pexiganan-
evolved strains, C: procedural control unselected strains, 1: present, 0: absent).
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